In this prospective, multicentre cohort study, we analysed specific prognostic factors and the impact of timing of highly active antiretroviral therapy (HAART) on disease progression and death among 625 human immunodeficiency virus (HIV)-1-infected, treatment-naïve patients diagnosed with an AIDS-defining disease. HAART was classified as early (<30 days) or late (30-270 days). Deferring HAART was significantly associated with faster progression to a new AIDS-defining event/death overall (p0.009) and in patients with Pneumocystis jiroveci pneumonia (p0.017). In the multivariate analysis, deferring HAART was associated with a higher risk of a new AIDS-defining event/death (p0.002; hazard ratio 1.83; 95% CI 1.25-2.68). Other independent risk factors for poorer outcome were baseline diagnosis of AIDS-defining lymphoma, age >35 years, and low CD4+ count (<50 cells/μL). Copyright © 2013 European Society of Clinical Microbiology and Infectious Diseases197 July 2013 10.1111/j.1469-0691.2012.03991.x INFECTIOUS DISEASES Original Articles ORIGINAL ARTICLE © 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.
- Advanced patients
- AIDS-defining events
- Pneumocystis jiroveci pneumonia
- Prognostic factors
- Timing of HAART